EMD Serono, USA
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany

Immunology: Modulating pathogenic mechanisms

Immunology: Modulating pathogenic mechanisms

Expanding our Expertise in Immunology

Our strength in biotherapeutics and immune-based therapies creates possibilities for novel approaches in major areas of high medical need across a number of immunological diseases.
Our research in immunology focuses on discovering new therapies that have the potential to modulate key pathogenic mechanisms in systemic lupus erythematosus, osteoarthritis, rheumatoid arthritis, psoriasis and other diseases.
With patients at the center of our efforts, we combine approaches that target:
  • T- and B-cell biology
  • cytokines & chemokines pathways
  • cartilage biology / repair mechanisms

Immunology Science in Action

Current projects in our development pipeline in this therapeutic area include:
  • Sprifermin – Fibroblast Growth Factor 18
  • Atacicept – Anti-Blys/anti-APRIL fusion protein
  • M1095 ALX - 0761 - Anti IL-17 A/F nanobody
  • M2951 – BTK inhibitor